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The control of the protozoan parasite Leishmania relies on few drugs with unknown cellular targets and unclear mode of action.
Several antileishmanials, however, were shown to induce apoptosis in Leishmania and this death mechanism was further
studiedindrug-sensitiveanddrug-resistantLeishmaniainfantum.Insensitiveparasites,antimonials(SbIII),miltefosine(MF)and
amphotericin B (AMB), but not paromomycin (PARO), triggered apoptotic cell death associated with reactive oxygen species
(ROS). In contrast, Leishmania mutants resistant to SbIII, MF or AMB not only failed to undergo apoptosis following exposure to
their respective drugs, but also were more tolerant towards apoptosis induced by other antileishmanials, provided that these
killed Leishmania via ROS production. Such tolerance favored the rapid acquisition of multidrug resistance. PARO killed
Leishmania in a non-apoptotic manner and failed to produce ROS. PARO resistance neither protected against drug-induced
apoptosis nor provided an increased rate of acquisition of resistance to other antileishmanials. However, the PARO-resistant
mutant, but not SbIII-, MF- or AMB-resistant mutants, became rapidly cross-resistant to methotrexate, a model drug also not
producing ROS. Our results therefore link the mode of killing of drugs to tolerance to cell death and to a facilitated emergence of
multidrug resistance. These ﬁndings may have fundamental implications in the ﬁeld of chemotherapeutic interventions.
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The bactericidal mode of action of antibiotics has recently
been shown to depend less on their primary target, and more
on the induction of common downstream effector mechan-
isms leading to cell death. Indeed, the generation of oxidants
has been a unifying step of such common death mechanisms
(reviewed in Kohanski et al.
1). Similarly, the induction of
apoptosis by several anticancer drugs has been suggested to
occur through the generation of oxidants, and a characteristic
feature of drug-resistant neoplasic cells seems to be their
ability to evade drug-induced apoptosis.
2,3 These studies
suggested a causal link between evolutionary-conserved
cellular events leading to death and the mode of action of
cytotoxic compounds, and highlighted the importance of
understanding the mode of action of drugs in order to
understand and prevent the emergence of drug resistance.
Apoptotic features have also been reported in the eukar-
yotic parasite Leishmania following exposure to several
drugs.
4–8 Leishmania are unicellular parasites responsible
for a wide range of human diseases ranging from self-healing
cutaneous lesions to fatal visceral infections. Anti-Leishmania
therapy relies on the use of a handful number of drugs
including pentavalent antimony (SbV)—a prodrug that needs
to be reduced to its trivalent state (SbIII) in order to acquire
antiparasitic activity, the polyene antibiotic amphotericin B
(AMB) and the phosphocholine analog miltefosine (MF).
9 A
phase 3 clinical trial has also been successfully completed for
the aminoglycoside paromomycin (PARO),
10 leading to its
approval for the treatment of visceral leishmaniasis in India.
Althoughthemechanismsresponsiblefortheanti-Leishmania
activities of these compounds have not yet been clearly
established, their primary targets are thought to differ
substantially. Indeed, evidence suggests that antimony have
a rather complex mode of action, acting at the level of multiple
cellular targets.
11–18 The leishmanicidal activity of MF has
been associated with perturbation of the metabolism of alkyl-
phospholipids, and the biosynthesis of alkyl-anchored glyco-
lipidsandglycoproteins.
19,20ThecytotoxicactivityofAMBhas
been associated with its high afﬁnity for ergosterol,
21 the main
sterol in the plasma membrane of fungi and Leishmania.
22
Finally, PARO, which interferes with protein synthesis by
binding to ribosomes in bacteria, was also shown to affect
translation in Leishmania,
23 in addition to alter the composi-
tion and ﬂuidity of the plasma membrane of the parasite.
24,25
Most antileishmanials were shown to induce apoptosis
features in Leishmania, which include an increase in
intracellular calcium levels, an accumulation of reactive
oxygenspecies(ROS),adropofthemitochondrialmembrane
potential (Dcm), genomic DNA degradation, exposure of
phosphatidyl serine and induction of caspase-like activ-
ity.
7,16,17,26,27 Interestingly, the antimony-resistant phenotype
of ﬁeld isolates was reported to be accompanied by a
decreased propensity to undergo apoptosis following expo-
sure to either SbIII, MF or AMB.
7 Therefore, it is possible that
the common mechanisms involved in cell killing described for
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could favor the development of resistance against other
drugs.
In this study, we sought to determine the putative apoptotic
features induced by SbIII, MF, AMB and PARO in Leishmania
infantum drug-sensitive and drug-resistant parasites, and to
assess whether an increased tolerance to apoptosis might
accompany the selection of drug resistance. Our results are
suggesting two types of drug-induced death in Leishmania,
andarelinkingthemodeofkillingtotolerancetocelldeathand
to a facilitated emergence of multidrug resistance.
Results
Drug-induced accumulation of ROS in the Leishmania
mitochondria. As several drugs were shown to induce
apoptosis in Leishmania, we ﬁrst studied the accumulation of
ROS upon drug exposure in the context of drug sensitivity
and resistance. The L. infantum Sb2000.1, MF200.5,
AMB1000.1 and PARO1200.1 cell lines were selected for
resistance to SbIII, MF, AMB and PARO, respectively, in a
stepwise manner until they reached at least a 10-fold
increased resistance compared with the parental clonal
strain (Table 1). None of the mutants showed marked
cross-resistance, with the exception of the SbIII- and
PARO-resistant mutants, which were ﬁve to six times
hypersensitive to MF (Table 1). The accumulation of ROS
was measured using the dichloroﬂuorescein diacetate
(DCFDA) dye whose ﬂuorescence intensity is indicative of
the levels of intracellular ROS.
28 L. infantum-sensitive
parasites subjected to increasing concentrations of SbIII,
MF and AMB exhibited a dose-dependent increase in
DCFDA ﬂuorescence signals (Figure 1), conﬁrming
increased ROS production upon exposure to these
antileishmanials. Pentamidine, another anti-Leishmania
drug, also induced the accumulation of ROS in sensitive
L. infantum (Supplementary Figure S1A) and so was the
classical apoptosis-inducing drug staurosporine
29
(Supplementary Figure S1C). In contrast, no ROS
production could be measured by DCFDA ﬂuorescence in
the resistant mutants Sb2000.1, MF200.5 and AMB1000.1
exposed to the drug deﬁning their resistance phenotype
(Figure 1). PARO behave differently as it failed to induce
ROS accumulation irrespective of the PARO susceptibility
status of the parasites (Figure 1). This was not unique to
PARO as we found that methotrexate (MTX), a model drug
often studied in Leishmania,
30,31 also failed to induce ROS in
Leishmania (Supplementary Figure S1B).
As the major source of oxidants in eukaryotes is the
mitochondria, we used the MitoSox dye (red mitochondrial
superoxide indicator) to measure the mitochondrial accumu-
lation of superoxide, which is an indicative measure of ROS
level in the mitochondria.
32 As expected, SbIII, MF and AMB
induced an increase in MitoSox ﬂuorescence levels in
sensitive but not resistant parasites (Figure 2a). Colocaliza-
tion experiments between DCFDA and mitotracker ﬂuores-
cence signals further conﬁrmed that the mitochondria were
the site of drug-induced ROS accumulation (Figure 2b). The
accumulation of superoxide within the mitochondria usually
results in a misregulation of cellular iron homeostasis through
the oxidation of iron-sulfur clusters, which translates into the
production of highly active hydroxyl radicals via the Fenton
reaction.
4,33 The role of iron in the drug-induced accumulation
of oxidants was conﬁrmed by the reduced level of ROS
produced within the mitochondria of sensitive L. infantum
pretreated with the iron-chelating agent deferoxamine before
being exposed to increasing concentrations of SbIII, MF and
AMB (Figure 2c). The same protective effect against the
accumulation of ROS was observed in L. infantum parasites
pretreated with the antioxidant glutathione (GSH) (Figure 2c).
Every experiments presented so far were performed with
the more experimentally tractable promastigote insect stage
of the parasite. Accordingly, we tested whether a similar drug-
induced ROS accumulation could be observed with the more
clinically relevant intracellular amastigotes. MitoSOX-pre-
loaded promastigotes were used to infect macrophages and
the resulting intracellular sensitive parasites, but not their
resistant counterparts, accumulated ROS when exposed to
SbV (the prodrug that is converted to SbIII), MF or AMB
(Figure 2d).
Tolerance to drug-induced apoptosis in drug-resistant
Leishmania. As the accumulation of oxidants within the
mitochondria is one of the hallmarks of apoptosis including in
parasites,
34,35 we tested whether other apoptotic features
could be observed following exposure to different
antileishmanials. We monitored changes in the Dcm using
the tetramethylrhodamine ethyl ester (TMRE) dye,
7 a
cationic ﬂuorescent molecule whose accumulation within
the mitochondria is an indicative measure of the Dcm, and
tested for genomic DNA degradation by gel electrophoresis.
Table 1 Susceptibility of L. infantum WT and drug-resistant mutants to SbIII, MF, AMB, PARO and MTX
SbIII (lM) MF (lM) AMB (lM) PARO (lM) MTX (lM)
WT 49.6±9.6 16.3±5.4 0.040±0.013 80.9±39.3 255±23
Sb2000.1 42000** 3.3±0.5* 0.045±0.028 142.8±15.7* ND
MF200.5 116±24* 4200** 0.055±0.017 104.3±21.4 ND
AMB1000.1 97±3* 21±2.6 41000** 110.7±24.4 ND
PARO1200.1 50±1.4 2.8±0.4* 0.040±0.012 41680** 212±18
MTX1000.3 ND ND ND 60±17.6 41000**
Abbreviations: AMB, amphotericin B; MTX, methotrexate; MF, miltefosine; ND, not determined; PARO, paromomycin; WT, wild-type
*Po0.05; **Po0.01
EC50 were determined after 72h of culture in the presence of various drug concentrations as described
28
Results are the average of at least three independent experiments
Paired Student’s t-test (*Po0.05; **Po0.01)
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Cell Death and DiseaseA signiﬁcant drop in the Dcm was observed in sensitive cells
exposed to SbIII, MF and AMB, but not with PARO
(Figure 3a). Similarly, drug-induced DNA laddering
occurred in L. infantum wild-type cells treated with SbIII,
MF and AMB, but not with PARO (Figure 3b). Interestingly,
neither a decrease in Dcm nor a degradation of genomic
DNA could be observed in the drug-resistant mutants
exposed to their selective drugs (Figures 3a and b).
In contrast, the protonophore carbonyl cyanide
p-triﬂuoromethoxy-phenylhydrazone remained potent at
inducing a signiﬁcant loss in Dcm in these mutants
(Figure 3a), suggesting that the proton gradient was still
intact in the resistant parasites.
Having found that SbIII, MF, AMB, but not PARO, induced
several apoptosis features in drug-sensitive parasites but not
in the Sb2000.1-, MF200.5- and AMB1000.1-resistant lines,
respectively, we sought to understand whether a non-speciﬁc
tolerance to drug-induced apoptosis occurred in these
mutants. Interestingly, the Sb2000.1-, MF200.5- or
AMB1000.1-resistant mutants failed to produce ROS when
challenged with the drug used for their selection, and there
wasalsoasigniﬁcantlackofROSproductioninthesemutants
upon challenge with any of the ROS-inducing drugs
(Figure 4a). Again, the PARO1200.1 mutant behave differ-
ently as ROS levels comparable to wild-type cells were
observed in this mutant after a challenge with SbIII and even
higher levels were observed after a challenge with MF or AMB
(Figure 4a). The drop in Dcm following exposure either to
SbIII, MF or AMB was also lower in the Sb2000.1, MF200.5
and AMB1000.1 mutants than in the sensitive cells or the
PARO1200.1 mutant (Figure 4b). The modulation in ROS
production and change in Dcm were further correlated with
drug-induced laddering of genomic DNA. Indeed, no DNA
laddering was induced in the Sb2000.1, MF200.5 and
AMB1000.1 mutants following exposure either to SbIII, MF
or AMB, whereas the same drugs induced oligonucleosomal
fragmentation in the PARO1200.1 mutant (Figure 4c). We
also tested whether this phenomenon of cross-tolerance to
drug-induced apoptosis occurred with intracellular amasti-
gotes.WemeasuredROSinparasitesinfectingmacrophages
and we found that the Sb2000.1, MF200.5 and AMB1000.1,
but not PARO1200.1, failed to produce more ROS than the
control, when challenged with ROS-inducing drugs
(Figure 4d). As GSH was shown to protect cells against
drug-induced ROS (Figure 2c) and that GSH has been linked
to SbIII resistance,
36–39 we tested whether cells resistant to
ROS-inducing drugs had increased levels of reduced thiols.
However, analysis by HPLC failed to show a signiﬁcant
increase of reduced thiols in the drug-resistant mutants
(results not shown).
Tolerance to drug-induced cell death favors the
acquisition of multidrug resistance. We showed that the
tolerance to drug-induced apoptosis in the Sb2000.1,
MF200.5 and AMB1000.1 lines occurred not only against
the drug initially used for the selection of resistance but also
extended to any apoptosis-inducing drugs. We hypothesized
that this phenomenon may facilitate the emergence of multi-
resistance against other drugs, provided that these shared
similar killing effector mechanisms. We thus compared the
rates of selection of resistant parasites by plating 5 10
6
drug-sensitive or drug-resistant parasites in the presence of
MF, AMB or PARO at a concentration inhibiting the growth of
L. infantum wild-type parasites. SbIII was omitted as the
susceptibility to this drug varied between mutants (Table 1).
The AMB1000.1, MF200.5, PARO1200.1 and MTX1000.3
mutants yielded from 6.9 10
4 to 1.3 10
5 colonies, and a
plating efﬁciency of B10% when plated with their respective
Figure 1 Drug-induced ROS in Leishmania infantum wild-type and drug-resistant mutants. Drug-induced ROS accumulation in L. infantum cells. L. infantum WT or
L. infantum Sb.2000.1, MF200.5, AMB1000.1 and PARO1200.1 log-phase cultures, selected for resistance to SbIII, MF, AMB and PARO, respectively, were exposed to
increasing concentrations of drugs for 48h. Aliquots (500ml) were washed and incubated in the presence of DCFDA for 30min. Fluorescence was measured at 530nm and
normalized according to protein concentrations. Results are the average of three independent experiments. *Po0.05
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Cell Death and DiseaseFigure 2 Drug-induced ROS accumulation in Leishmania infantum mitochondria. (a) Log-phase cultures of L. infantum WT or L. infantum Sb.2000.1, MF200.5 and
AMB1000.1 drug-resistant mutants were preloaded with MitoSOX for 2h, washed and exposed to two concentrations of SbIII, MF or AMB for 48h. Aliquots (500ml) were
taken, washed and the ﬂuorescence was measured at 580nm. (b) ROS accumulation in Leishmania cells was visualized with the ﬂuorescent dye DCFDA and the
mitochondria-speciﬁcdye Mitotracker. Log-phasecultureswereexposedto drugsfor48h, washedand incubatedwith DCFDAandMitotrackerfor 30min each.Fluorescence
microscopy showed colocalization of the oxidant-dependent DCFDA and the mitochondria-speciﬁc Mitotracker in drug-treated cells. (i) Brightﬁeld, (ii) DCFDA ﬂuorescence,
(iii) Mitotracker ﬂuorescence, (iv) Merge. (c) Protection against drug-induced mitochondrial ROS accumulation. Log-phase cultures of WT and drug-resistant mutants were
preloadedwith MitoSOXfor2h,washed,preincubatedwith Hepes–NaCl(barsa), 500mM ofdeferoxamine (barsb),orwith 2mMGSH(barsc)for24h,washedandexposed
totwoconcentrationsofSbIII, MFor AMBfor 48h. Aliquots(500ml) weretaken,washedandtheﬂuorescencewas measuredat 580nm.(d)Drug-induced ROSaccumulation
within intramacrophagic L. infantum. L. infantum WT (black bars), Sb2000.1 (white bars, left panel), MF200.5 (white bars, central panel) and AMB1000.1 (white bars, right
panel) promastigotes containing a luciferase expression vector were preloaded with MitoSOX, and subsequently used to infect J774 macrophages. The drug-induced ROS
accumulation in intracellular parasites was measured 48h post infection,andﬂuorescence (RFU)was normalizedto luciferase activity level (RLU). Results are the averageof
at least three independent experiments. *Po0.05; **Po0.01
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Cell Death and Diseasedrugs (Figure 5). In contrast, the wild-type cells did not yield
any colony when plated in the presence of MF or PARO, and
on an average 14 colonies were counted on the AMB plates
(Figure 5a). Remarkably, the L. infantum Sb2000.1 and
MF200.5 mutants generated signiﬁcantly more colonies on
the AMB plate than the L. infantum wild-type strain or the
PARO1200.1 mutant (Figure 5a). Similarly, the AMB1000.1
mutant yielded signiﬁcantly more colonies under MF
pressure than wild-type parasites or the PARO 1200.1
mutant (Figure 5a). However, the Sb2000.1 mutant
behaved unexpectedly, as few colonies were observed on
MF-containing plates (Figure 5a). This is probably due to the
fact that Sb2000.1 is ﬁvefold hypersensitive to MF (Table 1).
In the presence of PARO, the MF200.5 and AMB1000.1
mutantsdidnotyieldsigniﬁcantlymorecoloniesthanwild-type
parasites (Figure 5a). Again, the Sb2000.1 behaved in an
unexpected manner, producing a very high number of
colonies on PARO plates (Figure 5a). This observation might
be explained in part by the fact that the Sb2000.1 mutant
initially exhibited a slight but signiﬁcant cross-resistance to
PARO (Table 1). Although PARO and MTX did not induce
ROS in wild-type parasites (Figure 1 and Supplementary
Figure S1), it is not clear whether similar killing effector
mechanisms are shared by both drugs. Nonetheless, it is
intriguing that the MTX-resistant mutant yielded more
colonies than the MF200.5 mutant or wild-type parasites in
the presence of PARO (Figure 5b), and that the PARO1200.1
mutant also yielded a higher number of colonies on MTX-
containing plates than wild-type or MF200.5 cells (Figure 5b).
Discussion
Our study has revealed that anti-Leishmania compounds kill
byatleasttwo differentmechanisms, withSbIII,AMB, MFand
most likely pentamidine killing by apoptosis, and PARO and
the model drug MTX acting through another lethal mechan-
ism. In order to be classiﬁed as apoptosis-inducing drugs,
compounds were required to fulﬁll a number of criteria,
including the induction of mitochondrial ROS, a drop in Dcm
and genomic DNA degradation. Several studies had already
reported on the role of redox pathways in the increased
survival of Leishmania in the presence of SbIII,
18,38,39 with
iron potentiating the antileishmanial activity of SbIII.
4 Our
results indicate that this is probably valid for all drugs inducing
ROS, as experiments under iron-depleted conditions demon-
strated a key role for iron in drug-induced ROS production
(Figure 2c).
The dichotomy in the mode of killing between antileishma-
nials was further reinforced by the observation that cells
resistant to SbIII, MF and AMB were tolerant to apoptosis not
only against the initial selective drug but also against all drugs
sharingasimilarmodeofkilling.Thistoleranceislikelytoarise
by alterations in shared death pathways. Obviously, altera-
tions in these pathways do not lead to high-level cross-
resistance (Table 1) but can contribute to a decreased
propensity to undergo apoptosis, thereby favouring the
emergence of more speciﬁc resistance mechanisms. For
example, although no speciﬁc mutations leading to a high
level of AMB resistance are present in Sb2000.1 or MF200.5
cells (Table 1), an alteration in a death pathway allowing
tolerance to AMB-induced apoptosis may likely be shared by
these mutants (Figure 4). In contrast, as PARO kills through a
different mechanism, we did not observe tolerance to SbIII-,
MF- or AMB-induced apoptosis in the PARO-resistant mutant
(Figure 4). We are currently searching for phenotypic features
related to PARO and MTX killing as this would allow to test
whether non-ROS-producing drugs constitute a distinct class
of unrelated compounds that also share similar killing
mechanisms.
Such tolerance to drug-induced killing accelerated the
emergence of cross-resistance. Indeed, the SbIII-, MF- and
AMB-resistant mutants, but not the PARO-resistant mutant,
became more easily cross-resistant to the apoptosis-inducing
drugs SbIII, MF and AMB. Conversely, the PARO- and MTX-
resistant mutants acquired cross-resistance to the non-ROS-
producing drugs more easily. Two exceptions were noted,
both involving the Sb2000.1 mutant when plated with either
MF or PARO. This could possibly be explained by collateral
hypersusceptibility or cross-resistance already present in this
mutant (Table 1), where a mutation leading to resistance or
susceptibility may supersede alteration(s) in a death pathway
when cross-resistance is selected. As SbIII interferes with the
thiol redox metabolism,
18 it is possible that oxidant-induced
Figure 3 Drug-induced apoptosis in Leishmania. Drug-induced loss of Dcm
(a) and gDNA laddering (b) in sensitive and resistant Leishmania cells. Log-phase
cultures were exposed to drugs (SbIII, 400mM; MF, 25mM; AMB, 0.2mM;
and PARO, 280mM) or to saline buffer (control) for 48h. (a) For measuring Dcm,
a 500-ml aliquot was washed, incubated with TMRE for 30min, washed and the
ﬂuorescence was measured (545nm). Fluorescence was normalized to protein
concentrations. (b) Genomic DNA degradation was investigated by analyzing the
isolated gDNA on 1.3% agarose gels. Results represent the average of at least
three independent experiments and are expressed as percentage of the control.
**Po0.01; ***Po0.001. MW: 1kb Plus Ladder (Invitrogen)
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Cell Death and Diseasemutational events occurred speciﬁcally in the Sb2000.1
mutant and led to increased PARO resistance (Figure 5a).
This would be reminiscent of bactericidal antibiotic-induced
mutagenesis in bacteria.
40
The present results suggest that Leishmania parasites
resistant to SbIII, MF or AMB in the ﬁeld could be more prone
at acquiring multidrug resistance to these antileishmanials,
while retaining sensitivity to PARO. These conclusions are
supported by the observation that ﬁeld isolates resistant to
SbIIIwerelesspronetoundergoapoptosisfollowingexposure
toeitherSbIII,MFor AMB.
7A recentstudy alsosuggestedthe
possible cross-resistance of L. donovani ﬁeld isolates to SbIII,
MF and AMB in areas of endemicity.
41 Drug combination is
now an important strategy in our ﬁght against infectious
diseasesandthishasnowrecentlybeenshowntobeeffective
in Leishmania.
42 Our data provide a rationale for combining
drugs with different modes of killing.
In summary, there are at least two effector mechanisms
for anti-Leishmania drugs. Resistance is accompanied by
tolerance to drug-induced apoptosis not only against the
selectivedrugbutalsoagainstdrugssharingasimilarmodeof
killing. This cross-tolerance leads to a facilitated emergence
of cross-resistance against other drugs that have different
cellular targets but similar mode of killing.
Materials and Methods
Leishmania strains and culture conditions. L. infantum (MHOM/MA/67/
ITMAP-263) and the drug-resistant mutants L. infantum Sb2000.1, L. infantum
MF200.5, L. infantum AMB1000.1 and L. infantum PARO1200.1 (resistant to
2000mM SbIII, 200mM MF, 1mM AMB and 1680mM PARO, respectively) were
grown in SDM-79 medium supplemented with 10% fetal bovine serum at 251C.
Drug susceptibilities were obtained as described. Log-phase parasites were
preincubated with deferoxamine (500mM) or GSH (2mM) for 24h before being
washed and subsequently exposed to drugs for 48h. To determine apoptotic
features (ROS, Dcm and gDNA laddering), log-phase cultures were exposed to
toxic drug concentrations for 48h in order to trigger apoptosis.
Measurement of ROS accumulation. Intracellular ROS accumulation
was measured using the DCFDA dye (Invitrogen, Burlington, Ontario, Canada) as
described.
28 Brieﬂy, DCFDA is cell permeant and non-ﬂuorescent. Upon its entry
into live cells, the diacetate groups are cleaved by cellular esterases. Oxidation of
the reduced dye occurs in the presence of ROIs, causing ﬂuorescence. After drug
exposure(48h),parasiteswerecentrifugedat3000r.p.m.,washed,resuspendedin
500ml of Hepes–NaCl (21mM Hepes, 137mM NaCl, 5mM KCl, 0.7mM
Na2HPO4.7H2O, 6mM glucose, pH 7.4) and incubated for 30min in presence of
DCFDA (40nM). After washing, 200ml of the promastigote resuspension was
analyzed with a Victor ﬂuorometer (Perkin–Elmer, Turku, Finland) at 485nm
excitation and 535nm emission wavelengths. Fluorescence was normalized with
proteins concentration measured using the 2D QuantKit (GE Healthcare, Quebec,
Canada). A similar procedure was used with the MitoSOX dye (Invitrogen, Ontario,
Canada) to determine the ROS accumulation occurring within the mitochondrion.
MitoSOX is a live-cell permeant, and rapidly and selectively targets the
Figure 4 Cross-tolerance to drug-induced apoptosis in Leishmania drug-resistant mutants. The accumulation of ROS (a and d), loss of Dcm( c) and gDNA degradation
(b) were measured in Leishmania WT and resistant mutants (Sb2000.1, MF200.5, AMB1000.1 and PARO1200.1). Promastigotes log-phase cultures (a, b and c) were left
untreated (controls, bars a) or exposed to 400mM SbIII (bars b), 25mM MF (bars c), 0.2mM AMB (bars d) or 280mM PARO (bars e) for 48h. Aliquots were washed and
incubatedinthepresenceof(a)DCFDA(ROS)or(b)TMRE(Dcm)for30min.Fluorescencewasmeasuredat530nm(DCFDA)or545nm(TMRE)andnormalizedtoprotein
concentrations.(c)GenomicDNAwasanalyzedon1.3%agarosegelsMW:1kbPlusLadder(Invitrogen).(d)AccumulationofROSweremeasuredinintracellularLeishmania
wild-type cells and drug-resistant mutants. Puriﬁed metacyclics were preloaded with DCFDA and used to infect THP-1 macrophages. Infected cells were then left untreated
(controls, bars a) or treated with 150mM of Pentostam (SbV) (bars b), 1mM of MF (bars c), 0.05mM of AMB (bars d) or 30mM of PARO (bars e). Results are the average of
three independent experiments and are expressed as percentage of controls (a, b and d).* Po0.01; **statistically different from * with Po0.01
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Cell Death and Diseasemitochondria. Once in the mitochondria, the MitoSOX probe is oxidized by
superoxide, hence, exhibiting a red ﬂuorescence (580nm).
Measurement of ROS accumulation in intracellular
amastigotes. Luciferase-containing promastigotes were harvested in stationary
growth phase (6 days), and metacyclics were puriﬁed using the peanut agglutinin
assay.
43 Brieﬂy, 10ml of stationary-phase cultures were centrifuged at 3000r.p.m.,
washed and resuspended in 10ml Hepes–NaCl containing 100mg/ml of the lectin
peanut agglutinin (Sigma-Aldrich, Ontario, Canada), and incubated with agitation for
30min at room temperature. The mixture was then centrifuged at 900r.p.m.,the
metacyclic-containing supernatants were collected and centrifuged at 3000r.p.m., and
the pellet was washed and resuspended in appropriate Hepes-NaCl volume. Puriﬁed
metacyclics were preincubated with 40nM of DCFDA for 20min, washed and used for
subsequent macrophages infection as described.
44 At 3h after infection, macrophages
were washed to remove non-phagocytized parasites. Drugs at EC50 levels: Pentostam
(SbV,150mM),MF(1mM),AMB(0.05mM)orPARO(30mM)wereadded.After2days,
DCFDA ﬂuorescence was taken to measure oxidants accumulation within the
amastigotes parasites. Macrophages were then lysed and processed in order to
measure luminescence from luciferase-expressing amastigotes as a measure of
survival to normalize oxidants-induced ﬂuorescence.
MeasurementofDwmandgDNAladdering. Dcmwasmeasuredusing
the cationic lipophilic ﬂuorescent TMRE dye as described.
7 Fluorescence was
normalized with proteins concentrations as described above. gDNA was harvested
from untreated and treated parasites using a method previously described.
7 In all,
10mg of gDNA was loaded on a 1.3% agarose gel and was allowed to migrate at
90V for 1h.
Mitochondrial localization of drug-induced ROS using
ﬂuorescence microscopy. After drug exposure (48h), parasites were
centrifugedat3000r.p.m.,washedandresuspendedin500mlofHepes—NaCl,and
were coincubated for 30min in presence of both DCFDA (40nM) and Mitotracker
(40nM). Parasite were subsequently centrifuged at 3000r.p.m., washed and
resuspended in 500ml of Hepes—NaCl, and 20ml of parasite suspension was
layered on poly-L-lysine-coated microscope slides under a cover slips. Slides were
analyzed using a ﬂuorescence microscope (Nikon eclipse TE300 ﬂuorescence
microscope; Nikon, Ontario, Canada) using typical green and red ﬁlters. Images
were captured using Image Pro Plus 5.0 software (Media Cybernetics, Inc.,
Bethesda,MD,USA).Atleast20microscopicﬁeldswereobservedforeachsample.
Cross-resistance selection on drug-containing SDM-agar
plates. Equal number (5 10
6) of wild-type or drug-resistant parasites were
centrifuged at 3500r.p.m., washed two times in Hepes—NaCl and resuspended in
50ml Hepes-NaCl, and subsequently plated on SDM-agar plates containing either
0.24mM of AMB, 80mMo fM Fo r4 8 0mM of PARO. These concentrations, which
corresponded to six times the EC50 of the wild-type strain, were the lowest allowing
minimal growth of wild-type parasites. Colonies were counted after 14 days. Plating
was repeated at least three independent times.
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